Impact of cumulative inflammation, cardiac risk factors and medication exposure on coronary atherosclerosis progression in rheumatoid arthritis.
This article is protected by copyright. All rights reserved Individuals with RA experience a higher rate of cardiovascular events (CVE) compared with controls (1) . We recently reported greater prevalence, severity, burden, and vulnerability of occult coronary plaque in RA compared with age and gender-matched individuals without autoimmunity (2) . Increasing atherosclerosis burden on serial CCTA is an independent predictor of acute coronary syndromes in both men and women without autoimmune disease (3, 4) . In contrast, stabilization in plaque size is associated with decreased risk of future CVE (5) . Changes in coronary plaque load and composition in RA are largely unexplored. Two recent reports evaluated determinants of incident CAC or prevalent CAC progression and described associations with age, higher blood pressure and triglyceride levels but no disease-specific traits or treatments (6, 7) . However, CAC represents roughly 20% of total plaque burden in both RA and general patients and may not be present in earlier disease (2, 8) ; more importantly, additional information on plaque burden, stenotic severity and composition exclusively rendered by CCTA significantly improves upon predictive value of CAC for CVE in general patients (9) .
In the present study we explored incident coronary plaque rates, prevalent atherosclerosis progression and plaque composition change in a cohort of RA patients with baseline and follow-up CCTA. We further identified determinants of increasing plaque and CAC burden and specifically interrogated the role of cumulative inflammation, cardiac risk factors, RA-specific or ancillary medications and their interactions on plaque progression.
We hypothesized that higher cumulative inflammation might predict greater coronary plaque load at follow-up; we further posited that duration of exposure to RA-specific medications such as glucocorticoids, conventional synthetic and biologic DMARDs (csDMARDs and bDMARDs respectively), traditional cardiac risk factors and statin treatments may exert opposing effects on plaque growth or composition.
MATERIALS AND METHODS

Patient Recruitment
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This article is protected by copyright. All rights reserved One hundred-one patients who participated in a prior CCTA study of subclinical coronary atherosclerosis in RA (2) underwent follow-up assessments after 83±3.6 months.
Participants had been prospectively followed at our outpatient rheumatology clinic since 2010 to 2011 (baseline visit). Inclusion and exclusion criteria have been described in detail elsewhere (2) . Briefly, patients were enrolled if they met the 2010 classification criteria for RA, were ≥18 years of age and had no symptoms or history of cardiovascular disease at baseline. Major exclusion criteria were concomitant autoimmune syndromes except for Sjogren's Syndrome, weight >325 pounds (147.7 kg), iodine allergy, glomerular filtration rate <60ml/min, malignancy, and chronic or active infections. The study was approved by the local Institutional Review Board and signed informed consent was obtained from all participants in accordance with the Declaration of Helsinki.
Predictor variables
Hypertension constituted SBP ≥140mmHg or DBP ≥90mmHg or antihypertensive use. Diabetes mellitus encompassed HgbA1c>6.5%, or hypoglycemic medication use.
Hyperlipidemia was defined as fasting cholesterol >200 mg/dl, or LDL>130 mg/dl or statin use. Smoking entailed cigarette consumption within 30 days from screening. Waist-to-height ratio (WHtR) was used as a measurement of central obesity (10). Screening for incident cardiac risk factors was conducted according to EULAR recommendations for CV risk assessment. Disease activity was evaluated by 28-joint counts and c-reactive protein (DAS28-CRP) at every clinic visit (11) . Cumulative inflammatory burden was calculated as a time-averaged CRP spanning all visits between baseline and follow-up scans (12) .
Medications were reconciled at every clinic visit; including use and doses of prednisone, conventional synthetic disease modifying antirheumatic drugs (csDMARDs), bDMARDs and statins. Total prednisone and methotrexate doses from baseline to follow-up were calculated; years exposure to bDMARD and statins were also estimated.
Laboratory evaluations
Complete blood counts, comprehensive metabolic panels, erythrocyte sedimentation rate (ESR) and CRP were completed on the day of both CCTA assessments as well as on
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This article is protected by copyright. All rights reserved every clinic visit in-between scans. Fasting lipid evaluations were carried out on the days of both scans as well as according to EULAR recommendations for CV risk assessment inbetween scans (11) .
Multi-Detector Coronary Computed Tomography Angiography (CCTA)
Baseline scans were performed with a 64-multidetector row Lightspeed VCT scanner (GE Healthcare) between 3/2010-3/2011; follow-up scans were carried out in a 256multidetector row scanner between 3/2017-3/2018. Baseline and follow-up images were analyzed in the same campaign and in random order by a single, blinded interpreter (MJB) (13) . CAC was quantified by the Agatston method (14) . Coronary arteries were evaluated on contrast-enhanced scans using a standardized 17-segment American Heart Association model (15) . For longitudinal comparisons, baseline and follow-up coronary segments were coaligned using fixed anatomic landmarks as fiducial points. Each segment was scored for stenosis severity on a 0 to 4 scale based on grade of luminal restriction, where 0 = 0% (absence of plaque), 1 = 1-29% stenosis, 2 = 30-49% stenosis, 3 = 50-69% stenosis, and 4 = >70% (2) . Plaque composition was defined as non-calcified (NCP), mixed (MP), or calcified (CP) as reported elsewhere (16) . Subjects received two individual quantitative scores (16); segment involvement score (SIS) represented the total number of segments with plaque; segment stenosis score (SSS) described the cumulative stenosis grade rendered by plaque in all evaluable segments. Reproducibility of these scoring measures for our institution has been previously reported (16) .
Outcome variables
Changes in burden of total plaque, specific plaque types (NCP, MP, CP) and CAC constituted the primary outcome variables. Atherosclerosis progression was defined as the number of new segments with any plaque per patient (SIS increase, range 0-17) or rise in stenotic plaque severity in all evaluable coronary segments with plaque (SSS increase, range 0-68). CAC progresion was expressed as the absolute difference between the second and first measurement of coronary artery calcium [CAC (follow-up) -CAC (baseline) ].
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Statistical analysis
Continuous variables were expressed as means with 95% confidence intervals (CI) or standard deviations (SD) unless otherwise described; categorical variables were expressed as numbers with percentages. Negative binomial regression was used to assess count outcomes (SIS and SSS increase), robust logistic regression for dichotomous outcomes (NCP, MP, and CP progression), and generalized linear models with a Tweedie (Poisson-Gamma) error distribution and log link function for CAC change. For each outcome, univariable models with candidate predictors were estimated, followed by multivariable models constructed via a backward elimination variable selection process. The backward selection process started with all predictors associated with the outcome in univariable analyses at the level of P<0.20 and sequentially removed variables with P>.10, beginning with the least significant variable. For primary outcomes, the possible presence of interactions between cumulative inflammation and traditional risk factors was tested by introducing into the adjusted multivariable models the product of time-averaged CRP with each CV risk factor and medication exposure variable. Age and the time between scans were included as covariates in all models. Analyses were carried out in SPSS.
RESULTS
Participants were predominantly female with established, seropositive, erosive, and well-controlled disease ( Table 1) . Follow-up included an average of nineteen visits over seven years. Forty-eight patients were considered plaque progressors based on either displaying new coronary segments with plaque (SIS change range 0-6) or increased stenotic severity in segments with prior plaque (SSS change range 0-9). Clinical characteristics of progressors and non-progressors are presented in table 1; RA-related parameters and treatments were similarly distributed across both groups including time on csDMARDs, bDMARDs, total prednisone and methotrexate doses. Although progressors were older, more obese, hypertensive and with higher time-averaged SBP compared to nonprogressors, those differences were no longer significant after adjusting for age. Progressors more commonly had plaque and CAC, as well as higher plaque and CAC scores at baseline
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This article is protected by copyright. All rights reserved (p<0.05). Eight incident CVE occurred throughout the observation period (supplementary table 1); four were ischemic and 4 non-ischemic. All patients with events remained in the study and were included in the analysis. 
Incident plaque rates, plaque progression and calcification over time
Determinants of change in coronary atherosclerosis burden
Older age, higher TA-CRP and greater total prednisone dose independently predicted both SIS increase as well as SSS increase in multivariate models ( Table 2 ). The effect of TA-CRP on total plaque increase was modified by statin use, since TA-CRP predicted SIS increase only in patients unexposed to statins or receiving statins <50% of the study period, but not those receiving statins >50% of the time [p for interaction = 0.017, Figure 2A ).
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This article is protected by copyright. All rights reserved CAC change was independently predicted by age, obesity, TA-CRP, and total prednisone dose ( Table 2 ). Statin exposure also modified the effect of TA-CRP on CAC change; specifically, higher TA-CRP significantly associated with CAC change only in statinunexposed patients but not those with any statin exposure during the study period (P for interaction = 0.006, Figure 2B ). Additionally, the effect of TA-CRP on CAC change was moderated by TA-SBP; specifically, TA-CRP significantly predicted CAC change for patients in the middle (126<TA SBP<138mmHg) and highest (TA-SBP>138mmHg) tertiles but not those in the lowest tertile of TA-SBP (P for interaction = 0.023, Figure 2C ). 
DISCUSSION
This is the first study exploring predictors of coronary plaque progression in a well characterized, prospective cohort of RA patients without known cardiovascular disease and a long-term follow-up. We specifically interrogated the effects of cumulative inflammation, traditional cardiac risk factors, RA-specific and ancillary therapies and their interactions on
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This article is protected by copyright. All rights reserved progression of total plaque, various plaque subtypes and coronary calcification. Our findings, therefore, complement and enrich prior reports on CAC progression in RA (6, 7) .
We report several novel findings: First, higher cumulative inflammation was a consistent and independent predictor of total coronary plaque progression in RA; this included new segments with plaque on follow-up, as well as greater stenosis severity in segments with plaque at baseline. This is consistent with two prior reports that higher inflammatory burden was associated with carotid plaque progression in RA (17, 18) . Our observation, however, is of unique significance since the presence of carotid plaque in inflammatory joint diseases-including RA-do not sufficiently identify patients with coronary artery disease and since quantitative measurements of carotid atherosclerosis do not correlate with presence or burden of coronary plaque (19) . We used time-averaged CRP as a surrogate of cumulative inflammation; in supplementary analyses similar results were observed using time-averaged swollen joint counts as a predictor, but not when timeaveraged tender joint counts, time-averaged patient global assessments (PGA) or composite indices such as DAS28-CRP or CDAI were used. Importantly, higher cumulative inflammation in RA, was associated with greater future CVE risk (20) , while reduction in time-averaged inflammation yielded lower CVE risk (21) . Since atherosclerosis progression on serial CCTA independently predicted CVE in general patients (3, 5) , our observations collectively reaffirm that stringent and durable control of inflammation should be a primary objective in our quest to mitigate cardiovascular risk in RA.
Second, higher cumulative inflammation may additionally promote plaque remodeling and maturation as evidenced by its strong association with CAC and CP progression.
Indeed, 56 of 117 (48%) segments with CP at follow-up had no plaque at baseline; ostensibly, incident plaques appeared in those segments as NCPs that grew and matured over periods of inflammation during disease flares. As inflammation subsided, they eventually transitioned to advanced, heavily CP. Support for this timeline was provided in supplementary analyses, where we demonstrated that the within-patient variability in CRP over time significantly predicted CAC progression independently of age, hypertension, obesity and baseline CAC (p=0.018). Concordantly, previous reports confirmed that in early
This article is protected by copyright. All rights reserved atherogenesis inflammation drives and co-localizes with initial intimal calcification (22) ; in response to proinflammatory cytokine production by macrophages at sites of lipid accumulation, vascular smooth muscle cells (VSMC) undergo apoptosis, release extracellular vesicles secondary to stress, or undergo phenotype transition to osteoblastic cells, as a self-preservation strategy. All those events associate with local calcification, which is initially undetectable on CCTA (22) . If inflammation persists, macrophage infiltration and microcalcifications progress, eventually appearing as spotty calcifications on CCTA. If inflammation subsides and the VSMC repair system is not overwhelmed (cells do not die by apoptosis in the meantime), this process will lead to calcified acellular plaques. Indeed, in advanced plaques, large, dense calcifications are spatially distinct from macrophages, inversely correlate with macrophage burden and-like the calcific mummification of soft tissue infections-represent healing that stabilizes the arterial wall (22) . Hence, higher burden of CP at follow-up may reflect the final stage in the life cycle of plaques that appeared and evolved in the context of a historically higher inflammatory load. Curiously, this association between inflammation and calcification was not observed in prior reports of CAC progression in RA (6, 7) . One potential explanation may be the longer duration of follow-up (7 years compared to ≤3 years) and greater number of evaluation points (19 compared to 2 or 3) in our study (6, 7) , allowing for a more comprehensive assessment of inflammation variability as well as adequate time for plaque remodeling thereof.
Our third novel finding is that longer bDMARD exposure may yield an atheroprotective effect in RA, independently of stringent control of systemic inflammation; specifically, lengthier bDMARD experience reduced the likelihood of NCP progression, the earliest histologically atherosclerotic lesion discernible on CCTA. Biologic therapies were similarly shown to selectively influence lipid-rich, soft plaque volume in patients with psoriasis (23) . Moreover, we showed that lengthier bDMARD exposure appeared to prevent maturation and remodeling of such plaques, as evidenced by the lower risk of progressive calcification, independently of inflammation, duration of statin exposure and total prednisone dose. In a similar fashion, bDMARDs have been shown to inhibit radiographic progression in RA regardless of attainment of optimal disease control (24) (25) (26) . By contrast, neither duration
This article is protected by copyright. All rights reserved of exposure to csDMARDs nor total methotrexate dose in our study influenced coronary plaque progression.
Fourth, we established an independent coronary atheroprotective effect of statins in RA; longer statin exposure associated with lower risk of NCP progression regardless of cumulative inflammation, total prednisone and methotrexate dose or bDMARD duration.
Indeed, stabilization or reduction in plaque size, particularly the non-calcific lipid core component, is well documented in response to high intensity statin therapy in general patients (27) (28) (29) (30) and related to lower risk of CVE (5) . However, the atheroprotective effect of statin in our study was not related to the treatment intensity but rather the duration of the exposure. Our additional observation that the duration of statin exposure moderated the effect of cumulative inflammation on both plaque and CAC progression, highlights potential local anti-inflammatory effects of statins at the plaque level (31), independently of systemic inflammation as reflected by blood CRP levels (32) .
Regrettably, sustained remission may be unrealistic for the majority of patients at the present time (33) . Could RA-specific or other ancillary treatments mitigate coronary plaque progression in subjects who do not achieve stringent inflammatory control? We observed that longer statin exposure additionally moderated the effect of inflammation on total plaque progression; in patients treated with statins>50% of the observation time, higher timeaveraged CRP failed to yield significant progression of either coronary plaque or CAC. We further noted that durable, aggressive systolic blood pressure (SBP) control throughout the observation period may be instrumental, particularly in the face of chronic residual inflammation; time-averaged SBP at the lowest tertile (<126mmHg) attenuated the effect of higher cumulative inflammation on CAC progression whereas higher measurements significantly accelerated it. Nevertheless, it is currently unclear whether atheroprotection in RA-specifically in the context of residual inflammation-requires adjustment of the recommendations for starting lipid lowering therapy or adoption of more rigorous SBP targets than in general patients (34) .
We additionally demonstrated that cumulative prednisone dose adversely affected total coronary plaque as well as CAC progression independently of cumulative inflammation
This article is protected by copyright. All rights reserved or cardiac risk factors. Despite the fact that physicians generally prescribe corticosteroids to patients with higher disease activity, our observation highlights the true deleterious effect of corticosteroids on the vascular wall rather than confounding by indication. Importantly, the duration of statin exposure in our study did not moderate this effect of total prednisone dose on coronary plaque progression, as previously reported for carotid atherosclerosis (17) .
Since higher cumulative prednisone dose has been linked to greater incidence of CVE in RA (35), timely de-escalation and withdrawal may be warranted.
Our study has certain limitations. First, the absence of a control group hinders us from determining whether the observed magnitude and predictors of plaque change in RA are different from subjects without autoimmunity. However, at least for CAC, where a precedent for comparison exists, the observed CAC progression in our patients was significantly higher than predicted based on age, gender, and ethnicity-matched reference values (relative risk, 2.21; 95% confidence interval 1.39 to 3.52, p=0.001) (36). Second, our patients had low cumulative inflammatory burden; 47% had time-averaged DAS28-CRP<2.4 and 68% had DAS28-CRP<2.8. Moreover, rigorous screening and management of incident cardiac risk factors occurred for all patients during their clinic visits. Additionally, patients with prevalent calcification or significant plaque burden on baseline CCTA were given at least statin therapy, if not more aggressive treatment for atherosclerosis and regardless of such requirement on clinical grounds. Consequently, the likelihood of plaque progression may have been attenuated in patients who were otherwise poised to exhibit the greatest increase. Accordingly, the proportions, magnitude of plaque progression and effect sizes of predictors thereof may have been attenuated compared to cohorts with higher disease activity or untreated risk factors.
Conclusion
Occult coronary atherosclerosis burden increased in a significant proportion of patients with RA. Cumulative inflammatory burden and total prednisone dose were disease specific, independent determinants of plaque progression. Our findings confirm the importance of prioritizing and targeting durable control of inflammation in RA. Longer exposure to biologics or statins as well as rigorous control of systolic blood pressure may
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This article is protected by copyright. All rights reserved further moderate the effect of inflammation on atherosclerosis progression and yield additional coronary atheroprotective effects beyond optimal control of systemic inflammation. Rheumatoid factor, ACPA: anti-cyclic citrullinated peptide antibodies, CRP: high-sensitivity c-reactive protein, SJC: swollen joint count, DAS28-CRP: disease activity score, LDL: lowdensity lipoprotein, cs-DMARD: conventional synthetic disease modifying anti-rheumatic drug, bDMARD: biologic disease modifying anti-rheumatic drug, SIS: segment involvement score, SSS: segment stenosis score, NCP: non-calcified plaque, MP: mixed plaque, CP: calcified plaque *p<0.05 for progressors vs. non-progressors, § number (n=49) of patients exposed to prednisone at anytime between baseline and follow-up scans, ¶ number (n=78) of patients exposed to bDMARDs at anytime between baseline and follow-up scans, † number (n=59) of patients exposed to statin at anytime between baseline and follow-up scans. OR: odds ratio, 95% CI: 95% confidence interval. † p<0.1, *p<0.05, **p<0.01, ***p<0.001. 
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